Identification of microtubule-associated biomarkers in diffuse large B-cell lymphoma and prognosis prediction

Abstract

Background: Diffuse large B-cell lymphoma (DLBCL) is a genetically heterogeneous disease with a complicated prognosis. Even though various prognostic evaluations have been applied currently, they usually only use the clinical factors that overlook the molecular underlying DLBCL progression. Therefore, more accurate prognostic assessment needs further exploration. In the present study, we constructed a novel prognostic model based on microtubule associated genes (MAGs).Methods: A total of 33 normal controls and 1360 DLBCL samples containing gene-expression from the Gene Expression Omnibus (GEO) database were included. Subsequently, the univariate Cox, the least absolute shrinkage and selection operator (LASSO), and multivariate Cox regression analysis were used to select the best prognosis related genes into the MAGs model. To validate the model, Kaplan-Meier curve, and nomogram were analyzed.Results: A risk score model based on fourteen candidate MAGs (CCDC78, CD300LG, CTAG2, DYNLL2, MAPKAPK2, MREG, NME8, PGK2, RALBP1, SIGLEC1, SLC1A1, SLC39A12, TMEM63A, and WRAP73) was established. The K-M curve presented that the high-risk patients had a significantly inferior overall survival (OS) time compared to low-risk patients in training and validation datasets. Furthermore, knocking-out TMEM63A, a key gene belonging to the MAGs model, inhibited cell proliferation noticeably.Conclusion: The novel MAGs prognostic model has a well predictive capability, which may as a supplement for the current assessments. Furthermore, candidate TMEM63A gene has therapeutic target potentially in DLBCL.

Identification and validation of hub genes and molecular classifications associated with chronic myeloid leukemia

“…Exosomal lncRNA LINC01268 is also a cancerpromoting factor for pancreatic cancer (29). NME/NM23 family member 8 (NME8) has been identified as a predisposition variant in breast cancer and a prognostic marker in diffuse large B-cell lymphoma (30,31). DMXL2 has also been proposed as a potential therapeutic target for breast cancer and oral mucosal melanoma (32, 33).…”

Molecular subtyping and prognostic risk characterization of head and neck squamous cell carcinoma based on lysosome-related genes

“…[ 17 ] Transmembrane protein 63A gene knockout can inhibit diffuse large B-cell lymphoma cell proliferation and is a potential therapeutic target. [ 18 ] Transmembrane 9 superfamily member 1 is a target of phosphorylated CTD interacting factor 1 and may mediate phosphorylated CTD interacting factor 1 oncogenic function. [ 19 ] Hook microtubule tethering protein 3 is an independent prognostic factor for prostate cancer [ 20 ] and is associated with cisplatin resistance in lung cancer.…”